An analysis was carried out to determine whether the serum NfL level, a possible biomarker of continuing neuroaxonal degeneration, was higher in the years leading up to and around the time of clinical onset, and thus could be a direct predictor of the MS prodromal process (Khalil et al., 2018[56]). This evidence concerns the gene NEFL and myeloid sarcoma.